Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 9/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | ATM | Q13315 | 2/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | BCR | P11274 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2300466 | 1.00 | MAPK1 (0.42) | MAPK1KDM4EMAPTAURKAMEN1 | |
| SCHEMBL2300898 | 0.83 | MAPK1 (0.43) | MAPK1MEN1KMT2AATMABL1 | |
| SCHEMBL2300903 | 0.83 | MAPK1 (0.43) | MAPK1MEN1KMT2AATMABL1 | |
| SCHEMBL13182180 | 0.81 | MAPK1 (0.38) | MAPK1KDM4EMEN1KMT2AATM | |
| SCHEMBL2300578 | 0.79 | MAPK1 (0.42) | MAPK1KDM4EMAPT | |
| SCHEMBL12426745 | 0.79 | KDM4E (0.41) | MAPK1KDM4EMAPTAURKAMEN1 | |
| SCHEMBL2300332 | 0.79 | KDM4E (0.41) | MAPK1KDM4EMAPTAURKAMEN1 | |
| SCHEMBL2300330 | 0.79 | KDM4E (0.41) | MAPK1KDM4EMAPTAURKAMEN1 | |
| SCHEMBL2300575 | 0.79 | MAPK1 (0.42) | MAPK1KDM4EMAPT | |
| SCHEMBL2301267 | 0.78 | ESR1 (0.50) | KDM4EMAPTAURKAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2351737-A1 | 3-Amino-1-arylpropyl indoles and aza-substituted indoles | F. Hoffmann-La Roche AG (CH) | 2011-08-03 | — | — | EP | disclosed |
| EP-2351737-A1 | 3-Amino-1-arylpropyl indoles and aza-substituted indoles | F. Hoffmann-La Roche AG (CH) | 2011-08-03 | — | — | EP | disclosed |
| US-7803830-B2 | 3-amino-1-arylpropyl indoles and AZA-substituted indoles and uses thereof | ROCHE PALO ALTO LLC (US) | 2010-09-28 | — | — | US | disclosed |
| US-7803830-B2 | 3-amino-1-arylpropyl indoles and AZA-substituted indoles and uses thereof | ROCHE PALO ALTO LLC (US) | 2010-09-28 | — | — | US | disclosed |
| US-20090099236-A1 | 3-Amino-1-arylpropyl indoles and AZA-substituted indoles and uses thereof | ROCHE PALO ALTO LLC | 2009-04-16 | — | — | US | disclosed |
| US-20090099236-A1 | 3-Amino-1-arylpropyl indoles and AZA-substituted indoles and uses thereof | ROCHE PALO ALTO LLC | 2009-04-16 | — | — | US | disclosed |
| US-7446118-B2 | 3-amino-1-arylpropyl indoles and aza-substituted indoles and uses thereof | ROCHE PALO ALTO LLC (US) | 2008-11-04 | — | — | US | disclosed |
| US-7446118-B2 | 3-amino-1-arylpropyl indoles and aza-substituted indoles and uses thereof | ROCHE PALO ALTO LLC (US) | 2008-11-04 | — | — | US | disclosed |
| US-7446118-B2 | 3-amino-1-arylpropyl indoles and aza-substituted indoles and uses thereof | ROCHE PALO ALTO LLC (US) | 2008-11-04 | — | — | US | disclosed |
| EP-1960355-A1 | 3-AMINO-1-ARYLPROPYL INDOLES AND AZA-SUBSTITUTED INDOLES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007062996-A1 | 3-AMINO-1-ARYLPROPYL INDOLES AND AZA-SUBSTITUTED INDOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-07 | — | — | WO | disclosed |
| US-20070123527-A1 | 3-Amino-1-arylpropyl indoles and aza-substituted indoles and uses thereof | ROCHE PALO ALTO LLC | 2007-05-31 | — | — | US | disclosed |
| US-20070123527-A1 | 3-Amino-1-arylpropyl indoles and aza-substituted indoles and uses thereof | ROCHE PALO ALTO LLC | 2007-05-31 | — | — | US | disclosed |
| US-20070123527-A1 | 3-Amino-1-arylpropyl indoles and aza-substituted indoles and uses thereof | ROCHE PALO ALTO LLC | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123527-A1 | 3-Amino-1-arylpropyl indoles and aza-substituted indoles and uses thereof | IDO1, RB1, AHR | MAPK1 3379/4885KDM4E 550/4885MAPT 3825/4885 |
| US-20090099236-A1 | 3-Amino-1-arylpropyl indoles and AZA-substituted indoles and uses thereof | IDO1, RB1, AHR | MAPK1 3379/4885KDM4E 550/4885MAPT 3825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.